Press Releases May 20, 2026 04:05 PM

AIMEI HEALTH TECHNOLOGY CO., LTD RECEIVES NASDAQ NOTICE REGARDING DELAYED QUARTERLY REPORT

Aimei Health Technology receives Nasdaq notice due to delayed Q1 2026 quarterly report filing

By Derek Hwang AFJK

Aimei Health Technology Co., Ltd announced that it received a notice from Nasdaq for delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026, making it non-compliant with Nasdaq listing rules. The company has 60 days to file the report or submit a plan to regain compliance or face potential delisting. The company is actively working to complete the filing and expects to resolve the issue.

AIMEI HEALTH TECHNOLOGY CO., LTD RECEIVES NASDAQ NOTICE REGARDING DELAYED QUARTERLY REPORT
AFJK

Key Points

  • Nasdaq issued a notice for Aimei Health Technology's delay in filing Q1 2026 quarterly report (Form 10-Q).
  • The company has 60 days to file or propose a compliance plan to avoid potential delisting.
  • Aimei Health Technology is a blank check company focused on healthcare innovation targets.
  • Sectors impacted include the healthcare innovation sector and capital markets related to special purpose acquisition companies (SPACs).

New York, NY, May 20, 2026 (GLOBE NEWSWIRE) -- Aimei Health Technology Co., Ltd (the “Company”) (Nasdaq: AFJK) today announced that on May 19, 2026, it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Quarterly Report”) with the U.S. Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The Quarterly Report was due on May 15, 2026.

The Notice has no immediate effect on the listing or trading of the Company’s securities on Nasdaq. However, if the Company fails to timely regain compliance with the Listing Rule, the Company’s securities will be subject to delisting from Nasdaq.

Under Nasdaq rules, the Company has 60 calendar days from the date of the Notice to either file the Quarterly Report or submit a plan to Nasdaq to regain compliance with Nasdaq’s listing rules. If a plan is submitted and accepted, the Company may be granted up to 180 calendar days from the Quarterly Report’s due date to regain compliance. If Nasdaq does not accept the Company’s plan, the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel.

The Company is working diligently to complete and file the Quarterly Report and expects to regain compliance with the Listing Rule.

This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

About Aimei Health Technology Co., Ltd

Aimei Health Technology Co., Ltd is a blank check company incorporated as a Cayman Islands exempted company with limited liability for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The Company’s efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although the Company intends to pursue prospective targets focused on healthcare innovation.

Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the federal securities laws. These statements are based on management’s current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.

For investor and media inquiries, please contact:

Aimei Health Technology Co., Ltd
10 East 53rd Street, Suite 3001
New York, NY 10022
Attention: Junheng Xie
Email: [email protected]


Risks

  • Failure to file the report or regain compliance may result in delisting from Nasdaq, impacting stock liquidity and valuation.
  • Underlying uncertainty in the company's business prospects as a blank check company without a completed business combination.
  • Regulatory scrutiny and operational risks tied to reporting delays and compliance with SEC and Nasdaq requirements, affecting investor confidence.

More from Press Releases

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions Jun 4, 2026 Telesat announces results of 2026 Annual General Meeting of shareholders Jun 4, 2026 TOMI Expands European Footprint with New Regulatory Approvals for Binary Ionization Technology Jun 4, 2026 Xos Makes Its GFX Debut with Electric Vehicles, Powertrain Technology, and Mobile Charging for Public Fleets Jun 4, 2026 Satellogic to Participate in June Investor Conferences Jun 4, 2026